Smith & Nephew plc Receives “Neutral” Rating from Credit Suisse (SN.)
Smith & Nephew plc (LON:SN.)‘s stock had its “neutral” rating reiterated by analysts at Credit Suisse in a research report issued to clients and investors on Tuesday, American Banking and Market News reports. They currently have a GBX 775 ($12.43) price objective on the stock.
A number of other firms have also recently commented on SN.. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note to investors on Tuesday. They now have a GBX 740 ($11.87) price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note to investors on Tuesday, October 1st. They now have a GBX 830 ($13.32) price target on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. Smith & Nephew plc currently has an average rating of “Hold” and an average target price of GBX 772.86 ($12.40).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.